OTCM
ESMC
Market cap1mUSD
Dec 01, Last price
0.16USD
1D
-8.77%
1Q
-44.64%
Jan 2017
47.62%
Name
Escalon Medical Corp
Chart & Performance
P/E
—
P/S
0.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
4.47%
Revenues
12m
-1.63%
Net income
-125k
L
CFO
-603k
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Escalon Medical Corp. develops, manufactures, markets, and distributes medical devices and pharmaceuticals in the area of ophthalmology in the United States and internationally. It offers A-Scan, which provides information about the internal structure of the eye; B-Scan, a diagnostic tool that supplies information to physicians where the media within the eye are cloudy or opaque; UBM, a high frequency/high resolution ultrasound device, which provides detailed information about the anterior segment of the eye; and Pachymeter that measures the thickness of cornea. The company also distributes intraocular gas products, such as C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; and manufactures and distributes a patented disposable universal gas kit that delivers the gas from the canister to the patient. In addition, it offers disposable surgical packs that are used in vitreoretinal surgery; and AXIS Image management system for managing images through the Web browser from various devices regardless of modality, manufacturer, or location. The company sells its products to medical institutions through independent sales representatives, a network of distributors, and internal sales employees. Escalon Medical Corp. was founded in 1987 and is headquartered in Wayne, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||